| pubmed-article:21377930 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:21377930 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:21377930 | lifeskim:mentions | umls-concept:C0013216 | lld:lifeskim |
| pubmed-article:21377930 | lifeskim:mentions | umls-concept:C0008976 | lld:lifeskim |
| pubmed-article:21377930 | lifeskim:mentions | umls-concept:C0007097 | lld:lifeskim |
| pubmed-article:21377930 | lifeskim:mentions | umls-concept:C0460004 | lld:lifeskim |
| pubmed-article:21377930 | lifeskim:mentions | umls-concept:C1522484 | lld:lifeskim |
| pubmed-article:21377930 | lifeskim:mentions | umls-concept:C0036525 | lld:lifeskim |
| pubmed-article:21377930 | lifeskim:mentions | umls-concept:C0034897 | lld:lifeskim |
| pubmed-article:21377930 | lifeskim:mentions | umls-concept:C0231174 | lld:lifeskim |
| pubmed-article:21377930 | lifeskim:mentions | umls-concept:C0205390 | lld:lifeskim |
| pubmed-article:21377930 | lifeskim:mentions | umls-concept:C1831978 | lld:lifeskim |
| pubmed-article:21377930 | lifeskim:mentions | umls-concept:C0344211 | lld:lifeskim |
| pubmed-article:21377930 | lifeskim:mentions | umls-concept:C1514162 | lld:lifeskim |
| pubmed-article:21377930 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:21377930 | pubmed:dateCreated | 2011-4-5 | lld:pubmed |
| pubmed-article:21377930 | pubmed:databankReference | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21377930 | pubmed:abstractText | No treatments are presently available to increase survival in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy. We aimed to assess efficacy and safety of zalutumumab, a human IgG1 monoclonal antibody targeting the epidermal growth factor receptor, for overall survival in such patients. | lld:pubmed |
| pubmed-article:21377930 | pubmed:language | eng | lld:pubmed |
| pubmed-article:21377930 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21377930 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:21377930 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21377930 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21377930 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21377930 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21377930 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:21377930 | pubmed:month | Apr | lld:pubmed |
| pubmed-article:21377930 | pubmed:issn | 1474-5488 | lld:pubmed |
| pubmed-article:21377930 | pubmed:author | pubmed-author:SørensenPerP | lld:pubmed |
| pubmed-article:21377930 | pubmed:author | pubmed-author:LisbySteenS | lld:pubmed |
| pubmed-article:21377930 | pubmed:author | pubmed-author:ClementPaul... | lld:pubmed |
| pubmed-article:21377930 | pubmed:author | pubmed-author:MachielsJean-... | lld:pubmed |
| pubmed-article:21377930 | pubmed:author | pubmed-author:RuzsaAgnesA | lld:pubmed |
| pubmed-article:21377930 | pubmed:author | pubmed-author:NielsenTinaT | lld:pubmed |
| pubmed-article:21377930 | pubmed:author | pubmed-author:SubramanianSo... | lld:pubmed |
| pubmed-article:21377930 | pubmed:author | pubmed-author:RepassyGaborG | lld:pubmed |
| pubmed-article:21377930 | pubmed:author | pubmed-author:LifirenkoIgor... | lld:pubmed |
| pubmed-article:21377930 | pubmed:author | pubmed-author:FlygareAnnika... | lld:pubmed |
| pubmed-article:21377930 | pubmed:copyrightInfo | Copyright © 2011 Elsevier Ltd. All rights reserved. | lld:pubmed |
| pubmed-article:21377930 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:21377930 | pubmed:volume | 12 | lld:pubmed |
| pubmed-article:21377930 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:21377930 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:21377930 | pubmed:pagination | 333-43 | lld:pubmed |
| pubmed-article:21377930 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:21377930 | pubmed:meshHeading | pubmed-meshheading:21377930... | lld:pubmed |
| pubmed-article:21377930 | pubmed:meshHeading | pubmed-meshheading:21377930... | lld:pubmed |
| pubmed-article:21377930 | pubmed:meshHeading | pubmed-meshheading:21377930... | lld:pubmed |
| pubmed-article:21377930 | pubmed:meshHeading | pubmed-meshheading:21377930... | lld:pubmed |
| pubmed-article:21377930 | pubmed:meshHeading | pubmed-meshheading:21377930... | lld:pubmed |
| pubmed-article:21377930 | pubmed:meshHeading | pubmed-meshheading:21377930... | lld:pubmed |
| pubmed-article:21377930 | pubmed:meshHeading | pubmed-meshheading:21377930... | lld:pubmed |
| pubmed-article:21377930 | pubmed:meshHeading | pubmed-meshheading:21377930... | lld:pubmed |
| pubmed-article:21377930 | pubmed:meshHeading | pubmed-meshheading:21377930... | lld:pubmed |
| pubmed-article:21377930 | pubmed:meshHeading | pubmed-meshheading:21377930... | lld:pubmed |
| pubmed-article:21377930 | pubmed:meshHeading | pubmed-meshheading:21377930... | lld:pubmed |
| pubmed-article:21377930 | pubmed:meshHeading | pubmed-meshheading:21377930... | lld:pubmed |
| pubmed-article:21377930 | pubmed:meshHeading | pubmed-meshheading:21377930... | lld:pubmed |
| pubmed-article:21377930 | pubmed:meshHeading | pubmed-meshheading:21377930... | lld:pubmed |
| pubmed-article:21377930 | pubmed:meshHeading | pubmed-meshheading:21377930... | lld:pubmed |
| pubmed-article:21377930 | pubmed:meshHeading | pubmed-meshheading:21377930... | lld:pubmed |
| pubmed-article:21377930 | pubmed:meshHeading | pubmed-meshheading:21377930... | lld:pubmed |
| pubmed-article:21377930 | pubmed:meshHeading | pubmed-meshheading:21377930... | lld:pubmed |
| pubmed-article:21377930 | pubmed:meshHeading | pubmed-meshheading:21377930... | lld:pubmed |
| pubmed-article:21377930 | pubmed:year | 2011 | lld:pubmed |
| pubmed-article:21377930 | pubmed:articleTitle | Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial. | lld:pubmed |
| pubmed-article:21377930 | pubmed:affiliation | Cliniques Universitaires Saint Luc, Brussels, Belgium. jean-pascal.machiels@uclouvain.be | lld:pubmed |
| pubmed-article:21377930 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:21377930 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:21377930 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:21377930 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:21377930 | pubmed:publicationType | Clinical Trial, Phase III | lld:pubmed |
